ZHENJUN YANG, Professor, Peking University, Beijing, China

Prof. Dr. ZHENJUN YANG, Professor, Peking University, Beijing, China

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 June 2020 in ACS Applied Materials & Interfaces
Verified
Journal Article
Closed access
SNShuaijian Ni
Shuaijian Ni
ZZZhenjian Zhuo
Zhenjian Zhuo
YPYufei Pan
Yufei Pan
YYYuanyuan Yu
Yuanyuan Yu
FLFangfei Li
Fangfei Li
GZGe Zhang
Ge Zhang

1 April 2014 in Biomaterials
Verified
Journal Article
Closed access
LLLiyu Li
Liyu Li
JHJianjun Hou
Jianjun Hou
XLXinjie Liu
Xinjie Liu
YGYujia Guo
Yujia Guo
YWYun Wu
Yun Wu
ZHENJUN YANG, Professor, Peking University, Beijing, ChinaZHENJUN YANG, Professor, Peking University, Beijing, China
ZHENJUN YANG, Professor, Peking University, Beijing, China

5 January 2018 in Medicinal Research Reviews
Verified
Journal Article
Closed access
PDF file
Changmai ChenChangmai Chen
Changmai Chen
ZHENJUN YANG, Professor, Peking University, Beijing, ChinaZHENJUN YANG, Professor, Peking University, Beijing, China
ZHENJUN YANG, Professor, Peking University, Beijing, China
Xinjing TangXinjing Tang
Xinjing Tang

18 March 2016 in Nature Communications
Verified
Journal Article
Open access
SYShenyi Yin
Shenyi Yin
YFYu Fan
Yu Fan
HZHanshuo Zhang
Hanshuo Zhang
Zhao ZhihuaZhao Zhihua
Zhao Zhihua
YHYang Hao
Yang Hao
JXJianzhong Xi
Jianzhong Xi
Downregulation of a predominantly hepatocyte-specific miR-122 is associated with human liver cancer metastasis, whereas miR-122-deficient mice display normal liver function. Here we show a functional conservation of miR-122 in the TGFβ pathway: miR-122 target site is present in the mouse but not human TGFβR1, whereas a noncanonical target site is present in the TGFβ1 5′UTR in humans and other primates. Experimental switch of the miR-122 target between the receptor TGFβR1 and the ligand TGFβ1 changes the metastatic properties of mouse and human liver cancer cells. High expression of TGFβ1 in human primary liver tumours is associated with poor survival. We identify over 50 other miRNAs orthogonally targeting ligand/receptor pairs in humans and mice, suggesting that these are evolutionarily common events. These results reveal an evolutionary mechanism for miRNA-mediated gene regulation underlying species-specific physiological or pathological phenotype and provide a potentially valuable strategy for treating liver-associated diseases.

1 December 2017 in Molecular Therapy Nucleic Acids
Verified
Journal Article
Open access
XSXinyun Song
Xinyun Song
XWXiaoxia Wang
Xiaoxia Wang
YMYuan Ma
Yuan Ma
ZLZicai Liang
Zicai Liang
ZHENJUN YANG, Professor, Peking University, Beijing, ChinaZHENJUN YANG, Professor, Peking University, Beijing, China
ZHENJUN YANG, Professor, Peking University, Beijing, China
HCHuiqing Cao
Huiqing Cao
Rapid progress has been made toward small interfering RNA (siRNA)-based therapy for human disorders, but rationally optimizing siRNAs for high specificity and potent silencing remains a challenge. In this study, we explored the effect of chemical modification at the cleavage site of siRNAs. We found that modifications at positions 9 and 10 markedly reduced the silencing potency of the unmodified strand of siRNAs but were well tolerated by the modified strand. Intriguingly, addition of the 2'-methoxyethyl (MOE) group at the cleavage site improved both the specificity and silencing activity of siRNAs by facilitating the oriented RNA-induced silencing complex (RISC) loading of the modified strand. Furthermore, we combined MOE modifications at positions 9 and 10 of one strand together with 2'-O-methylation (OMe) at position 14 of the other strand and found a synergistic effect that improved the specificity of siRNAs. The surprisingly beneficial effect of the combined modification was validated using siRNA-targeting endogenous gene intercellular adhesion molecule 1 (ICAM1). We found that the combined modifications eliminated its off-target effects. In conclusion, we established effective strategies to optimize siRNAs using site-specific MOE modifications. The findings may allow the creation of superior siRNAs for therapy in terms of activity and specificity.

1 September 2018 in Biomaterials
Verified
Journal Article
Open access
YMYuan Ma
Yuan Ma
YZYuejie Zhu
Yuejie Zhu
CWChao Wang
Chao Wang
DPDelin Pan
Delin Pan
SLShuang Liu
Shuang Liu
ZHENJUN YANG, Professor, Peking University, Beijing, ChinaZHENJUN YANG, Professor, Peking University, Beijing, China
ZHENJUN YANG, Professor, Peking University, Beijing, China
Lipid derivatives of nucleoside analogs have been highlighted for their potential for effective gene delivery. A novel class of nucleobase-lipids are rationally designed and readily synthesized, comprising thymine/cytosine, an ester/amide linker and an oleyl lipid. The diversity of four nucleobase-lipids termed DXBAs (DOTA, DNTA, DOCA and DNCA) is investigated. Besides, DNCA is demonstrated to be an effective neutral transfection material for nucleic acid delivery, which enbles to bind to oligonucleotides via H-bonding and π-π stacking with reduced toxicity in vitro and in vivo. Several kinds of nucleic acid drugs including aptamer, ssRNA, antisense oligonucleotide, and plasmid DNAs can be delivered by DXBAs, especially DNCA. In particular, G4-aptamer AS1411 encapsulated by DNCA exhibits cellular uptake enhancement, lysosome degradation reduction, cell apoptosis promotion, cell cycle phase alteration in vitro and duration prolongation in vivo, resulting in significant anti-proliferative activity. Our results demonstrate that DNCA is a promising transfection agent for G4-aptamers and exhibites bright application prospects in the permeation improvement of single-stranded oligonucleotides or plasmid DNAs.